Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


5th World Congress on Cancer Therapy

Atlanta, USA

Yeu Su

National Yang-Ming University, Taiwan

Title: Assessment of the stemness-suppressive effects of several SHP-1 activators in human colorectal cancer cells


Biography: Yeu Su


STAT3 activation has been shown to be associated with enhanced malignancy and metastasis in human colorectal cancer (CRC). Moreover, active STAT3 was reported to be critical for the proliferation and survival of human colorectal cancer stem cells (CRSCs). Accordingly, several STAT3 inhibitors have been shown to block both the viability and self-renewal of CRSCs. Th erefore, novel agents capable of reducing the levels of active STAT3 may help in treating CRC more eff ectively. Because STAT3 is activated mainly by the phosphorylation of its tyrosine 705, a dephos-phorylation of this phosphorresidue executed primarily by the SH2 domain-containing phosphatase 1 (SHP-1), results in its inactivation. In this study, we assessed whether three novel SHP-1 activators including Sorafenib, SC-43, and SC-2001 could suppress the stemness of HCT-116 and HT-29 human CRC cells. Even though all three SHP-1 activators not only inhibited sphere formation but also induced sphere shrinkage of both cell lines, SC-2001 was excluded due to its low potency. Subsequently, Sorafenib and SC-43 were shown to suppress the anchorage-independent growth in both CRC lines. Furthermore, two agents could inhibit the expression of several CRSC markers as well as reduce the CD133+/CD44+ subpopulations in these cells. Interestingly, SC-43 was much more potent than Sorafenib in reducing the stemness properties of two CRC lines which could be accounted by its higher effi cacy in reducing their active STAT3 levels. Since the dosages of both Sorafenib and SC-43 required for suppressing the stemness were signifi cantly lower than those for diminishing the active STAT3 levels, investigation of the possible involvement of some “off -target” eff ects in their CRSC-suppressive activities is currently underway.